
|Videos|November 17, 2021
Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency
Author(s)Saro Arakelians, PharmD
Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery
3
How Pharmacists Can Close the Opioid Addiction Care Gap
4
Advancing the Role of Pharmacy Technicians in Hazardous Drug Compounding
5









































































































































































































